Pain Home > Darvocet-N 100

In November 2010, the United States Food and Drug Administration (FDA) withdrew all medications that contain propoxyphene from the market. It has been determined that the risks of propoxyphene outweigh the possible benefits. In particular, the FDA was concerned about the drug's ability to cause serious changes in the heart rhythm, even at normal doses. Pharmacies will no longer sell this medication, and people who take it should stop and ask their healthcare provider for a more suitable pain medication.
 
Darvocet® (propoxyphene/acetaminophen) is a prescription drug approved to treat mild-to-moderate pain, with or without a fever. There are three different types of this medication, including:
 
For Darvocet-N 50 and Darvocet-N 100, the recommended dosage is 100 mg of propoxyphene napsylate and 650 mg of acetaminophen (equal to one Darvocet-N 100 tablet or two Darvocet-N 50 tablets) every four hours as needed for pain.
 
For Darvocet A500, the recommended dosage is 100 mg of propoxyphene napsylate and 600 mg of acetaminophen (one Darvocet A500 tablet) every four hours as needed for pain.
 
For Darvocet-N 100 and Darvocet A500, the maximum recommended dosage is six tablets per day. For Darvocet-N 50, the maximum recommended dosage is 12 tablets per day.
 
(Click Darvocet Dosage to find out how Darvocet dosing works for people with liver or kidney dysfunction and for tips on using this particular medicine.)
 
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Advertisement
Topics & Medications

Quicklinks

Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.